Direct Comparison of Commercial Porcine Circovirus Type 2 Vaccines under Field Conditions
Kansas State University scientists found the PCV2 vaccines to be effective in two experiments they conducted under field conditions. They noted that, while two of the vaccines resulted in similar overall average daily gain over the whole trial period, there were differences in the pigs' growth patterns.
19 February 2014
3 minute read
By: Two experiments were carried out at Kansas State University to compare directly the effects of commercially available porcine circovirus type 2 (PCV2) vaccines on growth and mortality rate of pigs under field condition in a farm with a history of porcine circovirus disease.
The results are reported by M.L. Potter and colleagues in the journal, Professional Animal Scientist.
In Experiment 1, a total of 1,470 pigs were used. Pigs (initially 8.8kg bodyweight) within sex (barrow or gilt) were allotted to control or one of two commercial PCV2 vaccines (1DS; Suvaxyn PCV2, Fort Dodge Animal Health, Fort Dodge, Iowa, or 2DS; Circumvent PCV, Intervet/Schering-Plough Animal Health, Millsboro, Delaware).
In Experiment 2, a total of 1,993 pigs (25.2±1.24 days of age; 7.4±1.70 kg bodyweight) were allotted within litter and sex to two different commercial PCV2 vaccine treatments (BI; CircoFLEX, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, or IN; Circumvent PCV, Intervet/Schering-Plough Animal Health).
On day 143, the one- and two-dose groups were 3.4 and 4.6kg heavier (P<0.05) than the control pigs, respectively, but there was no difference (P=0.33) between the two PCV2-vaccinated groups.
The 1DS and 2DS groups had greater average daily gain from days 0 to 143 (0.717 and 0.726 versus 0.694kg).
Pigs vaccinated in Experiment 2 using IN vaccine had a lower (P< 0.001) average daily gain from days 0 to 73 (nursery) but tended to have increased (P=0.06) average daily gain from days 73 to 155 (finishing) than pigs vaccinated using the one-dose BI vaccine.
Overall, average daily gain and mortality were similar (P≥0.14).
In Experiment 1, the commercial PCV2 vaccines evaluated in this study were both effective at increasing average daily gain, with no detectable differences between vaccines, concluded Potter and colleagues.
They added that vaccinating pigs using the BI or IN vaccines resulted in similar overall average daily gain but there were differences in growth pattern over time.
Reference
Potter M.L., Y. Jacela, J.R. Bergstrom, S.S. Dritz, M.D. Tokach, J.M. DeRouchey, R.D. Goodband and J.L. Nelssen. 2014. Direct comparison of commercial porcine circovirus type 2 vaccines under field conditions. Professional Animal Scientist. 30(1):80-85.
Further Reading
You can view the full report (fee payable) by clicking here.
Find out more about PCV2 / PMWS by clicking here.
February 2014
